PT3568397T - Compostos e a sua utilização no tratamento da esquistossomose - Google Patents

Compostos e a sua utilização no tratamento da esquistossomose

Info

Publication number
PT3568397T
PT3568397T PT187008321T PT18700832T PT3568397T PT 3568397 T PT3568397 T PT 3568397T PT 187008321 T PT187008321 T PT 187008321T PT 18700832 T PT18700832 T PT 18700832T PT 3568397 T PT3568397 T PT 3568397T
Authority
PT
Portugal
Prior art keywords
schistosomiasis
compounds
treatment
Prior art date
Application number
PT187008321T
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PT3568397T publication Critical patent/PT3568397T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT187008321T 2017-01-16 2018-01-15 Compostos e a sua utilização no tratamento da esquistossomose PT3568397T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1700692.5A GB201700692D0 (en) 2017-01-16 2017-01-16 Novel compounds and their use in the treatment of schistosomiasis

Publications (1)

Publication Number Publication Date
PT3568397T true PT3568397T (pt) 2022-05-02

Family

ID=58463315

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187008321T PT3568397T (pt) 2017-01-16 2018-01-15 Compostos e a sua utilização no tratamento da esquistossomose

Country Status (16)

Country Link
US (1) US11046700B2 (pt)
EP (1) EP3568397B1 (pt)
JP (1) JP7101683B2 (pt)
KR (1) KR102560528B1 (pt)
CN (2) CN110461848B (pt)
AU (1) AU2018207345B2 (pt)
ES (1) ES2912356T3 (pt)
GB (1) GB201700692D0 (pt)
HU (1) HUE058652T2 (pt)
MY (1) MY197442A (pt)
NZ (1) NZ755637A (pt)
PH (1) PH12019501642A1 (pt)
PT (1) PT3568397T (pt)
SG (1) SG11201906511SA (pt)
WO (1) WO2018130853A1 (pt)
ZA (1) ZA201905402B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700692D0 (en) * 2017-01-16 2017-03-01 Salvensis Novel compounds and their use in the treatment of schistosomiasis
GB201811695D0 (en) 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
CN110452177A (zh) * 2019-09-02 2019-11-15 南通大学 一种5-溴-4-氟-1h-吲唑的合成方法
WO2022079616A1 (en) * 2020-10-14 2022-04-21 Novartis Ag Compounds and compositions for the treatment of cryptosporidiosis
EP4731627A1 (en) 2023-06-21 2026-04-29 Merck Patent GmbH Imidazo[1,2-a]pyrazin derivatives and their use in the treatment of a helminth infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418328A (pt) * 2003-12-31 2007-05-02 Schering Plough Ltd controle de parasitas em animais pelo uso de derivados de imidazo [1,2-b]piridazina
JP2011144169A (ja) * 2009-12-18 2011-07-28 Ishihara Sangyo Kaisha Ltd イミダゾピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2544609T3 (es) 2010-12-17 2015-09-02 Bayer Intellectual Property Gmbh Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos
US8748435B2 (en) * 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
EP2920177A1 (en) 2012-11-19 2015-09-23 Novartis AG Compounds and compositions for the treatment of parasitic diseases
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
GB2550750A (en) * 2014-12-19 2017-11-29 Aberystwyth Univ Anthelmintic compounds
GB201700692D0 (en) * 2017-01-16 2017-03-01 Salvensis Novel compounds and their use in the treatment of schistosomiasis

Also Published As

Publication number Publication date
US20200123158A1 (en) 2020-04-23
US11046700B2 (en) 2021-06-29
JP7101683B2 (ja) 2022-07-15
EP3568397A1 (en) 2019-11-20
AU2018207345B2 (en) 2021-11-11
KR102560528B1 (ko) 2023-07-26
WO2018130853A1 (en) 2018-07-19
SG11201906511SA (en) 2019-08-27
CN110461848A (zh) 2019-11-15
ES2912356T3 (es) 2022-05-25
HUE058652T2 (hu) 2022-09-28
ZA201905402B (en) 2024-09-25
CN115322199A (zh) 2022-11-11
MY197442A (en) 2023-06-19
CN115322199B (zh) 2024-12-10
AU2018207345A1 (en) 2019-08-08
KR20190104180A (ko) 2019-09-06
BR112019014528A2 (pt) 2020-02-27
EP3568397B1 (en) 2022-04-13
GB201700692D0 (en) 2017-03-01
JP2020506172A (ja) 2020-02-27
CN110461848B (zh) 2022-09-20
PH12019501642A1 (en) 2020-03-09
NZ755637A (en) 2025-11-28

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
IL262092A (en) Humanized anti-pacap antibodies and uses thereof
IL285178A (en) Compounds and uses thereof
IL283268A (en) Methods and devices for treating a disease with biotherapeutics
IL280536A (en) Muscle targeting complexes and uses thereof
IL262240A (en) Anti-human vista antibodies and use thereof
EP3673947A4 (en) CATHETER AND CATHETER KIT
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
PT3494134T (pt) Polipéptidos artificiais e sua utilização
PT3681857T (pt) Fluorofenil-beta-hidroxietilaminas e sua utilização no tratamento de hiperglicemia
DK3610005T3 (da) Peptidligase og anvendelse deraf
IL251816B (en) A pharmaceutical combination comprising alvocidib and bromodomain (brd) inhibitor for use in the treatment of cancer
EP3682022A4 (en) HUMAN THERAPEUTIC TARGET MOLECULES AND MODULATORS THEREOF
DK3558260T3 (da) Kosmetisk sammensætning omfattende et chaga-ekstrakt og anvendelse deraf
SI3672948T1 (sl) Piridinamin-piridon in spojine pirimidinamin-piridona
PL3229794T3 (pl) Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego
PT3568397T (pt) Compostos e a sua utilização no tratamento da esquistossomose
PL3592355T3 (pl) Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego
HUE058289T2 (hu) Brómdomén és extraterminális protein inhibitor kombinációs terápia
EP3412273A4 (en) ROOT CHANNEL TREATMENT AND ROOT CHANNEL TREATMENT MATERIAL
PT3268374T (pt) Inibidores de kv1.3 e a sua aplicação médica
IL284514A (en) Halo-allylamine compounds and use thereof
IL281608A (en) Anti-human cd45rc antibodies and uses thereof
IL282157A (en) Compounds and therapeutic uses thereof
EP3766413A4 (en) BIOSENSOR LAMINATE AND BIOSENSOR